ecancer
@ecancer.org
ecancer is a charity with a mission to raise the standards of care for cancer patients across the world through education.
sac-TMT reduced the risk of disease progression or death by 41% and the risk of death by 32% vs chemo in advanced or recurrent endometrial cancer. Watch @bpothuri.bsky.social discuss TroFuse-005 trial👉 https://ow.ly/Pb5x51016ci #ESMO26 #EndometrialCancer #CancerResearch
#ESMO26: Risvutatug rezetecan improves PFS in relapsed/refractory osteosarcoma. Dr Lu Xie discusses the findings with ecancer. Watch here: https://ow.ly/Mnh35101628 #oncology #Osteosarcoma #OncologyResearch Peking University
Pembrolizumab monotherapy improves PFSl and QoL in advanced or recurrent dMMR endometrial cancer. Watch Dr Brian Slomovitz discuss his study👉https://ow.ly/urkJ51013wE #EndometrialCancer #ESMO26 #CancerResearch @GynCancerMD
Pembrolizumab improves PFS and QoL in dMMR advanced endometrial cancer - ecancer
Dr Brian Slomovitz speaks to ecancer about KEYNOTE-C93/GOG-3064/ENGOT-en15, a phase 3, randomised, open-label study of first-line pembrolizumab versus carboplat
ow.ly
Interim MOIO trial reveals routine de-escalation of checkpoint inhibitors based solely on initial response is not supported by prospective data. Watch Dr Gwenaëlle Gravis discuss the trial 👉https://ow.ly/Ak8851013qU @paoli_calmettes #ESMO26
AZUR-1: Dostarlimab alone achieved 68% sustained complete response at 12 months in dMMR/MSI-H locally advanced rectal cancer. Could IO spare patients chemo, radiotherapy & surgery? Watch here👉https://ow.ly/hBAx5100VhW @MeredithPelster @SCRIOncology #ESMO26 #RectalCancer
Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer - ecancer
Dr Meredith Pelster speaks to ecancer about the first results from the global registrational AZUR-1 trial, which evaluated dostarlimab monotherapy in patients w
ow.ly
Intismeran autogene + pembrolizumab reduces the risk of recurrence or death by 42% in resected stage IIB–IV melanoma, improving recurrence-free survival vs pembrolizumab alone. Watch Professor Georgina V Long AO speak to ecancer👉https://bit.ly/4zQGGtc #ESMO26
Intismeran plus pembrolizumab improves recurrence free survival in resected high risk melanoma - ecancer
Prof Georgina Long speaks to ecancer about the phase III INTerpath-001 trial, which evaluated the personalised mRNA-based neoantigen therapy intismeran autogene
bit.ly
Short course durvalumab remodels the tumour immune microenvironment in early stage triple negative breast cancer. Watch Dr Joana Ribeiro discuss her study👉https://ow.ly/6smM5100OzW Gustave Roussy 🏥 #ESMO26 #TripleNegativeBreastCancer #CancerResearch
Short course durvalumab remodels the tumour immune microenvironment in early stage triple negative breast cancer - ecancer
Dr Joana Ribeiro speaks to ecancer about the first results from the phase II UNLOCK 14 (POP-DURVA) trial, which evaluated short-course preoperative durvalumab m
ow.ly
ESMO26: Adding nivolumab to perioperative chemo shows no significant benefit in muscle invasive bladder cancer. Watch Prof Andrea Necchi discuss his study👉https://ow.ly/n5905100OnB @AndreaNecchi @MyUniSR #ESMO26 #BladderCancer #OncologyResearch
Adding nivolumab to perioperative chemo shows no significant benefit in muscle invasive bladder cancer - ecancer
Prof Andrea Necchi speaks to ecancer about the final analysis of the phase III CA017-078 trial, which compared neoadjuvant gemcitabine and cisplatin alone with
ow.ly
ESMO26: Perioperative apalutamide plus ADT improves event free survival in high risk localised prostate cancer. Watch Prof Alberto Briganti discuss his study👉https://ow.ly/M1m05100Okc @Albert0Briganti @MyUniSR
Perioperative apalutamide plus ADT improves event free survival in high risk localised prostate cancer - ecancer
Prof Alberto Briganti speaks to ecancer about the PROTEUS substudy, which evaluated perioperative apalutamide plus androgen deprivation therapy (ADT) alongside
ow.ly
ESMO 2026: Extended letrozole improves disease-free survival in hormone receptor-positive breast cancer: 15-year results. Watch Prof Eleftherios Mamounas discuss his study👉https://ow.ly/hmH65100Nz2 UF Health Cancer Institute #ESMO26 #BreastCancer #Oncology
Extended letrozole improves disease-free survival in hormone receptor-positive breast cancer: 15-year results - ecancer
Prof Eleftherios Mamounas talks to ecancer at ESMO 2026 about the final analysis of the phase III NSABP B-42 trial, evaluating extended adjuvant letrozole in po
ow.ly
AI tool identifies patients most likely to benefit from extended endocrine therapy in hormone receptor-positive breast cancer. Watch Professor Eleftherios Mamounas discuss his study👉https://ow.ly/2ZIX5100NyO UF Health Cancer Institute #ESMO26 #EndocrineTherapy #BreastCancer
Extended letrozole improves disease-free survival in hormone receptor-positive breast cancer: 15-year results - ecancer
Prof Eleftherios Mamounas talks to ecancer at ESMO 2026 about the final analysis of the phase III NSABP B-42 trial, evaluating extended adjuvant letrozole in po
ow.ly
The phase II AMPLIFY-7P trial evaluated camupepimut (ELI-002 7P) in resected KRAS-mutated pancreatic cancer. Watch Prof Eileen O'Reilly discuss the trial 👉 https://bit.ly/4soSBfp #ESMO26 Memorial Sloan Kettering Continuing Medical Education
Combining SG, EV and ZIM achieved an 83% ORR, including 3 complete responses, in previously untreated metastatic urothelial cancer. Watch Dr Randy Sweis, MD discuss TROPHY-U-01 trial👉 https://bit.ly/4BEEiYy #ESMO26 UChicago College
Sacituzumab govitecan combination shows promising activity in first line metastatic urothelial cancer - ecancer
Dr Randy Sweis speaks to ecancer about the phase Ib TROPHY-U-01 Cohort 7 study. The study evaluates sacituzumab govitecan combined with enfortumab vedotin an
bit.ly
Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC. Watch Dr Alex Spira discuss his study 👉https://ow.ly/vTsp50ZYsNp @AlexSpiraMDPhD @VCSpecialists #NSCLC #Oncology #WCLC2026
Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC - ecancer
Dr Alex Spira speaks to ecancer about a global phase I study that evaluates three doses of iza-bren (izalontamab brenitecan), an EGFR and HER3 bispecific antibo
ow.ly
At #ESMOGI26, Dr Kozo Kataoka discusses GALAXY data showing postoperative ctDNA can identify colorectal liver metastasis patients most likely to benefit from adjuvant chemotherapy. Watch the interview👉 https://bit.ly/4xxdpmA #CRC #ctDNA #MRD #PrecisionMedicine
ctDNA MRD status predicts survival and adjuvant chemo benefit in resected colorectal liver metastas - ecancer
Dr Kozo Kataoka speaks to ecancer about the ctDNA status and adjuvant chemotherapy after resection of colorectal liver metastases. The study found that the role
bit.ly
At #ESMOGI26, DrPark Memorial Sloan Kettering Cancer Center discusses GLEAM results. Zolbetuximab + gemcitabine and nab-paclitaxel did not improve survival in CLDN18.2-positive MPC, highlighting the need for better patient selection and combination strategies. Watch the video👉https://bit.ly/3UyJiN6
Zolbetuximab plus chemo in CLDN18.2-positive metastatic pancreatic cancer does not improve OS - ecancer
Dr Wungki Park speaks to ecancer about the phase II GLEAM study, which evaluated zolbetuximab plus gemcitabine and nab-paclitaxel in patients with claudin 18 is
bit.ly
At #ESMOGI26, Josep Tabernero discusses that adagrasib plus cetuximab achieved higher response rates, including more CRs, in previously treated KRAS G12C-mutated mCRC, but did not significantly improve PFS or OS vs chemotherapy. Watch the interview👉https://bit.ly/4qxthTJ
Adagrasib plus cetuximab shows activity but does not improve survival in KRAS G12C-mutated metastatic colorectal cancer - ecancer
Dr Josep Tabernero speaks to ecancer about the final analysis of the phase III KRYSTAL-10 trial evaluating adagrasib plus cetuximab as second-line treatment for
bit.ly
At #ESMOGI26, Dr Michele Milella discusses targeted intratumoural phosphorus-32 microparticles plus FOLFIRINOX in uLAPC, showing encouraging local disease control and supporting further study of this combined approach. Watch the interview👉https://bit.ly/4gPfULa
P-32 microparticle brachytherapy plus FOLFIRINOX shows promising local control in unresectable pancreatic cancer - ecancer
Dr Michele Milella speaks to ecancer about an open-label, multi-centre, randomised study of TaRgeted intratumoural placement of phosphorous-32 microparticles ad
bit.ly
At #ESMOGI26, Dr Nilo Azad (Hopkins Press) discusses early phase 1 results of dual RAS inhibition with zoldonrasib plus daraxonrasib in heavily pretreated KRAS G12D-mutated metastatic pancreatic cancer, showing encouraging activity and manageable safety. Watch interview👉https://bit.ly/3S6hM94
Zoldonrasib plus daraxonrasib targets KRAS G12D in metastatic pancreatic cancer with promising early results - ecancer
Dr Nilo Azad presents early phase 1 results of a novel dual RAS inhibition strategy using zoldonrasib and daraxonrasib in patients with heavily pretreated metas
bit.ly
At #EHA2026, Prof Martin Schrappe discusses that blinatumomab improved 4-year EFS to 83% vs 70% with intensive chemotherapy in high-risk paediatric B-ALL, while reducing relapse and severe treatment-related toxicities. Watch the interview👉https://bit.ly/3U8C56h
Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival - ecancer
Prof Martin Schrappe speaks to ecancer about a randomized trial that evaluated whether blinatumomab could safely replace highly intensive chemotherapy in childr
bit.ly
At #EHA2026, Prof Marek Trněný (Charles University) discusses phase 2 CHEPA results showing brentuximab vedotin plus CHP and etoposide achieved a 91% ORR and 76% complete metabolic response rate in previously untreated CD30+ PTCL. Watch the interview👉https://bit.ly/4xlUgny #Lymphoma #Haematology
Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas - ecancer
Prof Marek Trněný speaks to ecancer about the phase 2 CHEPA study that evaluated the addition of etoposide to brentuximab vedotin plus CHP (CHEP) in prev
bit.ly
At #EHA2026, Prof Umberto Vitolo discusses phase 3 frontMIND results showing tafasitamab plus lenalidomide and R-CHOP reduced the risk of progression or death by 25% in previously untreated high-risk DLBCL. Watch interview👉https://bit.ly/4cOoYNX #DLBCL #Lymphoma #Haematology
Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma - ecancer
Prof Umberto Vitolo speaks to ecancer about the phase 3 frontMIND trial. This trial evaluated the addition of tafasitamab and lenalidomide to standard R-CHOP
bit.ly
At #EHA2026, Prof Umberto Vitolo discusses updated EPCORE DLBCL-3 results showing fixed-duration epcoritamab achieved a 73% ORR and 63% CR rate in frail, elderly patients with newly diagnosed DLBCL. Watch his interview👉https://bit.ly/4wzkKko #DLBCL #Haematology
Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma - ecancer
Prof Umberto Vitolo speaks to ecancer about the updated results from the phase 2 EPCORE DLBCL-3 trial evaluating fixed-duration epcoritamab monotherapy, a CD3&t
bit.ly
At #EHA2026, Prof Anthony Moorman (Newcastle University) discusses UKBlinPredict, using early MRD response and genetic markers such as IKZF1plus and DUX4 rearrangements to predict relapse risk after blinatumomab in B-ALL. Watch the interview👉 https://bit.ly/3RWO6ex #ALL #Haematology
Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL - ecancer
Prof Anthony Moorman speaks to ecancer about his study that evaluated outcomes in children and young people with chemotherapy-intolerant or resistant disease to
bit.ly
At #EHA2026, Prof Carsten Niemann discusses prospective validation of CLL-TIM, a machine-learning model predicting severe infection or treatment need within 2 years in newly diagnosed, asymptomatic CLL. Watch the full interview👉https://bit.ly/4x2NT8x #CLL #Haematology
CLL TIM risk model predicts infection and treatment need in newly diagnosed chronic lymphocytic leukaemia - ecancer
Prof Carsten Niemann speaks to ecancer about the first prospective, multicenter validation of the Chronic Lymphocytic Leukemia Treatment-Infection Model (CLL-TI
bit.ly
At #EHA2026, Dr Frederick Chen (Barts Health Archives) discusses UK ITP Registry data showing rapid and robust platelet responses with early romiplostim in acute ITP. Watch the full interview👉https://bit.ly/4cHSLb2 #ITP #Haematology
Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19 - ecancer
Dr Frederick Chen speaks to ecancer about real world evidence from the UK Adult ITP Registry evaluating the thrombopoietin receptor agonist romiplostim in acute
bit.ly
At #EHA2026, Prof Chan Cheah discusses phase 3 SOUNDTRACK F1 results showing surovatamig plus rituximab achieved response rates of 95–100% and CR rates of around 84–85% in previously untreated FL. Watch full interview👉 https://bit.ly/3RTR2si #FollicularLymphoma #Haematology
At #EHA2026, Prof David Kuter (Harvard Medical School) highlights the fatigue burden experienced by patients with chronic ITP, even when platelet counts are stable and bleeding is minimal. Watch hos full interview here👉 https://bit.ly/4gv8Mn8
Fatigue in adult ITP is common despite adequate platelet counts and minimal bleeding - ecancer
Prof David Kuter speaks to ecancer about his poster presentation that reports findings from a cross-sectional observational study evaluating fatigue in adults w
bit.ly
At #EHA2026, Prof Claire Harrison (Guy's and St Thomas') discusses results showing selinexor & ruxolitinib improved spleen responses in JAK inhibitor-naive MF, with nearly half achieving at least 35% spleen volume reduction & good survival outcomes. Watch the interview here👉 https://bit.ly/3TZ5Xlu
Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis - ecancer
Prof Claire Harrison speaks to ecancer about results from the phase 3 SENTRY trial evaluating selinexor, an XPO1 nuclear export inhibitor, in combination with r
bit.ly
At #EHA2026, Matthew Davids, MD, MMSc discusses phase 3 BRUIN CLL 322 results showing fixed-duration pirtobrutinib plus venetoclax and rituximab improved PFS vs SoC in previously treated CLL/SLL. Watch his interview👉https://bit.ly/4xYnE3x #CLL #Haematology #Oncology
Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL - ecancer
Dr Matthew Davids speaks to ecancer about results from the phase 3 BRUIN CLL 322 trial evaluating fixed-duration pirtobrutinib, a noncovalent BTK inhibitor, in
bit.ly